SCHEMBL2437263

SCHEMBL2437263

Nc1nc2cn[nH]c(=O)c2s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 1/20 0.41
SLC2A1 P11166 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
CDC7 O00311 7/20 0.36
CCNE1 P24864 7/20 0.36
CDK2 P24941 7/20 0.36
ROCK1 Q13464 7/20 0.36
DBF4 Q9UBU7 7/20 0.36
ALDH1A1 P00352 4/20 0.36
MAPT P10636 1/20 0.36
HSD17B10 Q99714 2/20 0.35
PARP1 P09874 1/20 0.35
PRKCI P41743 1/20 0.35
PDE4B Q07343 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CSNK2A1 P68400 1/20 0.32
CXCR2 P25025 1/20 0.32
TP53 P04637 1/20 0.32
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2441940 0.78 SLC2A1 (0.37) SLC2A1CDC7CCNE1CDK2ROCK1
SCHEMBL2445833 0.70 SLC2A1 (0.37) RPS6KA3SLC2A1SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL1273900 0.67 CCNE1 (0.46) CCNE1CDK2
SCHEMBL9550048 0.65 ALDH1A1 (0.46) RPS6KA3SLC2A1SMN1; SMN2CDK2ROCK1
SCHEMBL4403024 0.65 SLC2A1 (0.44) SLC2A1SMN1; SMN2ALDH1A1HSD17B10PARP1
SCHEMBL2442450 0.64 SLC2A1 (0.38) SLC2A1ALDH1A1HSD17B10PARP1PRKCI
SCHEMBL22993546 0.64 ALDH1A1 (0.55) SMN1; SMN2ALDH1A1MAPTHSD17B10TDP1
SCHEMBL30624728 0.63 ALDH1A1 (0.43) SLC2A1SMN1; SMN2ALDH1A1HSD17B10PARP1
SCHEMBL30334708 0.63 NOS1 (0.39) SLC2A1CDC7CCNE1CDK2ROCK1
SCHEMBL12292827 0.62 RPS6KA3 (0.43) RPS6KA3SMN1; SMN2ALDH1A1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-05-03 US disclosed
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-05-03 US disclosed
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-05-03 US disclosed
US-8017612-B2 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2011-09-13 US disclosed
US-8017612-B2 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2011-09-13 US disclosed
US-8017612-B2 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2011-09-13 US disclosed
EP-2009004-A1 NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR Japan Tobacco, Inc. (JP) 2008-12-31 EP disclosed
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2008-04-03 US disclosed
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2008-04-03 US disclosed
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors HAVCR2, AADAC, DNPEP RPS6KA3 3584/4885SLC2A1 3147/4885SMN1; SMN2 4462/4885
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR POLR1C, POLR2E, POLR2H RPS6KA3 3745/4885SLC2A1 4116/4885SMN1; SMN2 4299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.